The XMM-Newton serendipitous survey. VII. The third XMM-Newton serendipitous source catalogue

Thanks to the large collecting area (3 x ~1500 cm$^2$ at 1.5 keV) and wide field of view (30' across in full field mode) of the X-ray cameras on board the European Space Agency X-ray observatory XMM-Newton, each individual pointing can result in the detection of hundreds of X-ray sources, most of which are newly discovered. Recently, many improvements in the XMM-Newton data reduction algorithms have been made. These include enhanced source characterisation and reduced spurious source detections, refined astrometric precision, greater net sensitivity and the extraction of spectra and time series for fainter sources, with better signal-to-noise. Further, almost 50\% more observations are in the public domain compared to 2XMMi-DR3, allowing the XMM-Newton Survey Science Centre (XMM-SSC) to produce a much larger and better quality X-ray source catalogue. The XMM-SSC has developed a pipeline to reduce the XMM-Newton data automatically and using improved calibration a new catalogue version has been produced from XMM-Newton data made public by 2013 Dec. 31 (13 years of data). Manual screening ensures the highest data quality. This catalogue is known as 3XMM. In the latest release, 3XMM-DR5, there are 565962 X-ray detections comprising 396910 unique X-ray sources. For the 133000 brightest sources, spectra and lightcurves are provided. For all detections, the positions on the sky, a measure of the quality of the detection, and an evaluation of the X-ray variability is provided, along with the fluxes and count rates in 7 X-ray energy bands, the total 0.2-12 keV band counts, and four hardness ratios. To identify the detections, a cross correlation with 228 catalogues is also provided for each X-ray detection. 3XMM-DR5 is the largest X-ray source catalogue ever produced. Thanks to the large array of data products, it is an excellent resource in which to find new and extreme objects.Comment: 23 pages, version accepted for publication in A&

The XMM-Newton serendipitous survey: VIII. the first XMM-Newton serendipitous source catalogue from overlapping observations

Context. XMM-Newton has observed the X-ray sky since early 2000. The XMM-Newton Survey Science Centre Consortium has published catalogues of X-ray and ultraviolet sources found serendipitously in the individual observations. This series is now augmented by a catalogue dedicated to X-ray sources detected in spatially overlapping XMM-Newton observations. Aims. The aim of this catalogue is to explore repeatedly observed sky regions. It thus makes use of the long(er) effective exposure time per sky area and offers the opportunity to investigate long-term flux variability directly through the source-detection process. Methods. A new standardised strategy for simultaneous source detection on multiple observations was introduced, including an adaptive-smoothing method to describe the image background. It was coded as a new task within the XMM-Newton Science Analysis System and used to compile a catalogue of sources from 434 stacks comprising 1789 overlapping XMM-Newton observations that entered the 3XMM-DR7 catalogue, have a low background and full-frame readout of all EPIC cameras. Results. The first stacked catalogue is called 3XMM-DR7s. It contains 71 951 unique sources with positions and parameters such as fluxes, hardness ratios, quality estimates, and information on inter-observation variability, directly derived from a simultaneous fit. Source parameters are calculated for the stack and for each contributing observation. About 15% of the sources are new with respect to 3XMM-DR7. Through stacked source detection, the parameters of repeatedly observed sources are determined with higher accuracy than in the individual observations. The method is more sensitive to faint sources and tends to produce fewer spurious detections. Conclusions. With this first stacked catalogue we demonstrate the feasibility and benefit of the approach. It supplements the large data base of XMM-Newton detections with additional, in particular faint, sources and adds variability information. In the future, the catalogue will be expanded to larger samples and continued within the series of serendipitous XMM-Newton source catalogues.FJC acknowledges financial support through grant AYA2015-64346-C2-1P (MINECO/FEDER) and MTC through grant ESP2016-76683-C3-1R (MINECO/FEDER

The Evolution of Compact Binary Star Systems

We review the formation and evolution of compact binary stars consisting of white dwarfs (WDs), neutron stars (NSs), and black holes (BHs). Binary NSs and BHs are thought to be the primary astrophysical sources of gravitational waves (GWs) within the frequency band of ground-based detectors, while compact binaries of WDs are important sources of GWs at lower frequencies to be covered by space interferometers (LISA). Major uncertainties in the current understanding of properties of NSs and BHs most relevant to the GW studies are discussed, including the treatment of the natal kicks which compact stellar remnants acquire during the core collapse of massive stars and the common envelope phase of binary evolution. We discuss the coalescence rates of binary NSs and BHs and prospects for their detections, the formation and evolution of binary WDs and their observational manifestations. Special attention is given to AM CVn-stars -- compact binaries in which the Roche lobe is filled by another WD or a low-mass partially degenerate helium-star, as these stars are thought to be the best LISA verification binary GW sources.Comment: 105 pages, 18 figure

Expression and prognostic significance of THBS1, Cyr61 and CTGF in esophageal squamous cell carcinoma

<p>Abstract</p> <p>Background</p> <p>Thrombospondin1 (THBS1), cystene-rich protein 61 (Cyr61) and connective tissue growth factor (CTGF) are all involved in the transforming growth factor-beta (TGF-β) signal pathway, which plays an important role in the tumorigenesis. The purpose of this study is to explore the expression and prognostic significance of these proteins in esophageal squamous cell carcinoma (ESCC).</p> <p>Methods</p> <p>We used immunohistochemistry and western blotting to examine the expression status of THBS1, Cyr61 and CTGF in ESCC. Correlations of THBS1, Cyr61 and CTGF over-expressions with various clinicopathologic factors were also determined by using the Chi-square test or Fisher's exact probability test. Survival analysis was assessed by the Kaplan-Meier analysis and the log-rank test. Relative risk was evaluated by the multivariate Cox proportional hazards model.</p> <p>Results</p> <p>THBS1, Cyr61 and CTGF were all over-expressed in ESCC. THBS1 over-expression was significantly associated with TNM stage (<it>P </it>= 0.029) and regional lymph node involvement (<it>P </it>= 0.026). Kaplan-Meier survival analysis showed that over-expression of THBS1, Cyr61 or CTGF was related to poor survival of ESCC patients (<it>P </it>= 0.042, <it>P </it>= 0.020, <it>P </it>= 0.018, respectively). Multivariate Cox analysis demonstrated that Cyr61 and CTGF were independent factors in prognosis of ESCC.</p> <p>Conclusion</p> <p>Cyr61, CTGF and THBS1 were all over-expressed in ESCC and might be new molecular markers to predict the prognosis of ESCC patients.</p

Pathobiological Implications of MUC16 Expression in Pancreatic Cancer

MUC16 (CA125) belongs to a family of high-molecular weight O-glycosylated proteins known as mucins. While MUC16 is well known as a biomarker in ovarian cancer, its expression pattern in pancreatic cancer (PC), the fourth leading cause of cancer related deaths in the United States, remains unknown. The aim of our study was to analyze the expression of MUC16 during the initiation, progression and metastasis of PC for possible implication in PC diagnosis, prognosis and therapy. In this study, a microarray containing tissues from healthy and PC patients was used to investigate the differential protein expression of MUC16 in PC. MUC16 mRNA levels were also measured by RT-PCR in the normal human pancreatic, pancreatitis, and PC tissues. To investigate its expression pattern during PC metastasis, tissue samples from the primary pancreatic tumor and metastases (from the same patient) in the lymph nodes, liver, lung and omentum from Stage IV PC patients were analyzed. To determine its association in the initiation of PC, tissues from PC patients containing pre-neoplastic lesions of varying grades were stained for MUC16. Finally, MUC16 expression was analyzed in 18 human PC cell lines. MUC16 is not expressed in the normal pancreatic ducts and is strongly upregulated in PC and detected in pancreatitis tissue. It is first detected in the high-grade pre-neoplastic lesions preceding invasive adenocarcinoma, suggesting that its upregulation is a late event during the initiation of this disease. MUC16 expression appears to be stronger in metastatic lesions when compared to the primary tumor, suggesting a role in PC metastasis. We have also identified PC cell lines that express MUC16, which can be used in future studies to elucidate its functional role in PC. Altogether, our results reveal that MUC16 expression is significantly increased in PC and could play a potential role in the progression of this disease

Growth of a human mammary tumor cell line is blocked by galangin, a naturally occurring bioflavonoid, and is accompanied by down-regulation of cyclins D3, E, and A

INTRODUCTION: This study was designed to determine if and how a non-toxic, naturally occurring bioflavonoid, galangin, affects proliferation of human mammary tumor cells. Our previous studies demonstrated that, in other cell types, galangin is a potent inhibitor of the aryl hydrocarbon receptor (AhR), an environmental carcinogen-responsive transcription factor implicated in mammary tumor initiation and growth control. Because some current breast cancer therapeutics are ineffective in estrogen receptor (ER) negative tumors and since the AhR may be involved in breast cancer proliferation, the effects of galangin on the proliferation of an ER(-), AhR(high )line, Hs578T, were studied. METHODS: AhR expression and function in the presence or absence of galangin, a second AhR inhibitor, α-naphthoflavone (α-NF), an AhR agonist, indole-3-carbinol, and a transfected AhR repressor-encoding plasmid (FhAhRR) were studied in Hs578T cells by western blotting for nuclear (for instance, constitutively activated) AhR and by transfection of an AhR-driven reporter construct, pGudLuc. The effects of these agents on cell proliferation were studied by (3)H-thymidine incorporation and by flow cytometry. The effects on cyclins implicated in mammary tumorigenesis were evaluated by western blotting. RESULTS: Hs578T cells were shown to express high levels of constitutively active AhR. Constitutive and environmental chemical-induced AhR activity was profoundly suppressed by galangin as was cell proliferation. However, the failure of α-NF or FhAhRR transfection to block proliferation indicated that galangin-mediated AhR inhibition was either insufficient or unrelated to its ability to significantly block cell proliferation at therapeutically relevant doses (IC(50 )= 11 μM). Galangin inhibited transition of cells from the G(0)/G(1 )to the S phases of cell growth, likely through the nearly total elimination of cyclin D3. Expression of cyclins A and E was also suppressed. CONCLUSION: Galangin is a strong inhibitor of Hs578T cell proliferation that likely mediates this effect through a relatively unique mechanism, suppression of cyclin D3, and not through the AhR. The results suggest that this non-toxic bioflavonoid may be useful as a chemotherapeutic, particularly in combination with agents that target other components of the tumor cell cycle and in situations where estrogen receptor-specific therapeutics are ineffective

Anti-Heparanase Aptamers as Potential Diagnostic and Therapeutic Agents for Oral Cancer

Peer reviewe

Well-being in French Astrophysics

6 page conference proceedings on well-being in French astrophysicsIt has become clear that early career astrophysics researchers (doctoral researchers, post-docs, etc) have a very diverse appreciation of their career, with some declaring it the best job that you can have and others suffering from overwork, harrassment and stress from the precarity of their job, and associated difficulties. In order to establish how astrophysics researchers, primarily in France, experience their career, we sent out a survey to understand the impact that their job has on their well-being. 276 people responded to the survey. Whilst around half of the respondents expressed pleasure derived from their career, it is clear that many (early career) researchers are suffering due to overwork, with more than a quarter saying that they work in excess of 50 hours per week and 2\% in excess of 90 h per week. Almost 30\% professed to having suffered harrassment or discrimination in the course of their work. Further, whilst only 20\% had suffered mental health issues before starting their career in astrophysics, $\sim$45\% said that they suffered with mental health problems since starting in astrophysics. Here we provide results from the survey as well as possible avenues to explore and a list of recommendations to improve (early) careers in astrophysics

Development of novel single-stranded nucleic acid aptamers against the pro-Angiogenic and metastatic enzyme heparanase (HPSE1)

Heparanase is an enzyme involved in extracellular matrix remodelling and heparan sulphate proteoglycan catabolism. It is secreted by metastatic tumour cells, allowing them to penetrate the endothelial cell layer and basement membrane to invade target organs. The release of growth factors at the site of cleaved heparan sulphate chains further enhance the potential of the tumour by encouraging the process of angiogenesis. This leads to increased survival and further proliferation of the tumour. Aptamers are single or double stranded oligonucleotides that recognise specific small molecules, peptides, proteins, or even cells or tissues and have shown great potential over the years as diagnostic and therapeutic agents in anticancer treatment. For the first time, single stranded DNA aptamers were successfully generated against the active heterodimer form of heparanase using a modified SELEX protocol, and eluted based on increasing affinity for the target. Sandwich ELISA assays showed recognition of heparanase by the aptamers at a site distinct from that of a polyclonal HPSE1 antibody. The binding affinities of aptamer to immobilised enzyme were high (7×107 to 8×107 M−1) as measured by fluorescence spectroscopy. Immunohistochemistry and immunofluorescence studies demonstrated that the aptamers were able to recognise heparanase with staining comparable or in some cases superior to that of the HPSE1 antibody control. Finally, matrigel assay demonstrated that aptamers were able to inhibit heparanase. This study provides clear proof of principle concept that nucleic acid aptamers can be generated against heparanase. These reagents may serve as useful tools to explore the functional role of the enzyme and in the future development of diagnostic assays or therapeutic reagents